{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:05:20Z","timestamp":1792591520373,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.seizure.2025.11.016","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T07:06:57Z","timestamp":1763881617000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy and safety of cenobamate in developmental and epileptic encephalopathies: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5154-8717","authenticated-orcid":false,"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2025.11.016_bib0001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-024-00546-6","article-title":"Developmental and epileptic encephalopathies","volume":"10","author":"Scheffer","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.seizure.2025.11.016_bib0002","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109950","article-title":"Overview of clinical and physiologic aspects of status epilepticus in the developmental and epileptic encephalopathies","volume":"159","author":"Wirrell","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.11.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107612","article-title":"Management of Lennox-Gastaut syndrome beyond childhood: a comprehensive review","volume":"114","author":"Samanta","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.11.016_bib0005","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/epi.17932","article-title":"A comprehensive systematic literature review of the burden of illness of Lennox\u2013Gastaut syndrome on patients, caregivers, and society","volume":"65","author":"Cross","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2025.04.010","article-title":"Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies","volume":"168","author":"Samanta","year":"2025","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0007","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/epi4.12895","article-title":"Initial combination versus early sequential standard therapies for Infantile Epileptic Spasms Syndrome-Feedback from stakeholders","volume":"9","author":"Ramani","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2025.11.016_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110171","article-title":"A comprehensive review of evolving treatment strategies for Dravet syndrome: insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches","volume":"162","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.11.016_bib0009","article-title":"Antiseizure medications for Lennox-Gastaut Syndrome: comprehensive review and proposed consensus treatment algorithm","volume":"164","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.11.016_bib0010","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/14656566.2025.2516630","article-title":"Current and emerging pharmacotherapies in Lennox-Gastaut syndrome","volume":"26","author":"Samanta","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2025.11.016_bib0011","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0012","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.11.016_bib0013","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0014","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","article-title":"A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis","volume":"118","author":"Mulheron","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.11.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109653","article-title":"Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: a systematic review and network meta-analysis","volume":"152","author":"Tong","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.11.016_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: a Systematic Review and Network Meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2025.11.016_bib0018","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/epi.17549","article-title":"Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \"real-world\" retrospective study","volume":"64","author":"Pe\u00f1a-Ceballos","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0019","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14656566.2024.2373350","article-title":"Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies","volume":"25","author":"Dell'isola","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2025.11.016_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2025.03.012","article-title":"Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: a case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence","volume":"129","author":"Vlakou","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.11.016_bib0021","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2025.11.016_bib0022","first-page":"i4919","article-title":"Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance","volume":"355","author":"J\u00fcni","year":"2016","journal-title":"Br Med J"},{"key":"10.1016\/j.seizure.2025.11.016_bib0023","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0024","article-title":"Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy","volume":"13","author":"Agashe","year":"2023","journal-title":"Neurol Clin Pr"},{"key":"10.1016\/j.seizure.2025.11.016_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.seizure.2025.05.011","article-title":"Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: a multicenter real-world study in Spain","volume":"131","author":"Aguilar-Amat Prior","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.11.016_bib0026","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/epi.18308","article-title":"A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies","volume":"66","author":"Buhleier","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0027","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/epi.18426","article-title":"Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome","volume":"66","author":"Cagigal","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0028","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40120-025-00779-x","article-title":"Cenobamate for Adjunctive Treatment in Adult and Pediatric Patients with Refractory Lennox-Gastaut Syndrome: a Retrospective Chart Review","volume":"14","author":"Keough","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.seizure.2025.11.016_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110660","article-title":"Efficacy, safety and tolerability of adjunctive cenobamate in pediatric and adult patients with Lennox Gastaut Syndrome","volume":"172","author":"Pong","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.11.016_bib0030","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/epi.17427","article-title":"Successful treatment of adult Dravet syndrome patients with cenobamate","volume":"63","author":"Makridis","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0031","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pediatrneurol.2024.09.023","article-title":"Cenobamate's Efficacy for Seizure Treatment in Tuberous Sclerosis Complex","volume":"161","author":"Aungaroon","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0032","series-title":"American Epilepsy Society meeting. Los Angeles","article-title":"Hussain Shaun Cenobamate Treatment of Children with Refractory Epilepsy: the UCLA Experience","author":"Peters Haley","year":"2024"},{"key":"10.1016\/j.seizure.2025.11.016_bib0033","series-title":"American Epilepsy Society Annual Meeting","article-title":"Cenobamate Provides Significant Reduction in Seizure Activity in Patients with Infantile Spasms","author":"Sachdeo Rajesh","year":"2024"},{"key":"10.1016\/j.seizure.2025.11.016_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1209487","article-title":"Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction","volume":"14","author":"Friedo","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18586","article-title":"Real-world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: a multicenter retrospective series","author":"Soto-Insuga","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010129","article-title":"Treatment with Cenobamate in Adult Patients with Lennox-Gastaut Syndrome: a Case Series","volume":"12","author":"Falcicchio","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.seizure.2025.11.016_bib0037","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.18257","article-title":"Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy","volume":"66","author":"Gjerulfsen","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0038","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1111\/epi.17414","article-title":"Paroxysmal fast activity is a biomarker of treatment response in deep brain stimulation for Lennox-Gastaut syndrome","volume":"63","author":"Dalic","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0039","article-title":"Efficacy and safety of perampanel in patients with seizures associated with Lennox\u2013Gastaut syndrome: a randomized trial","author":"Vossler","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: a Randomized Clinical Trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0041","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.11.016_bib0042","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","article-title":"Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan","volume":"108","author":"Ohtsuka","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.11.016_bib0043","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJM199712183372504","article-title":"Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group","volume":"337","author":"Motte","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2025.11.016_bib0044","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1528-1157.2000.tb02179.x","article-title":"Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group","volume":"41","author":"Glauser","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0045","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2025.11.016_bib0046","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.11.016_bib0047","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1528-1157.1982.tb05085.x","article-title":"Sodium valproate: monotherapy and polytherapy","volume":"23","author":"Covanis","year":"1982","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0048","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.pediatrneurol.2014.06.004","article-title":"Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome","volume":"51","author":"Kim","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0049","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.braindev.2007.09.004","article-title":"Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: korean multicentric experience","volume":"30","author":"You","year":"2008","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2025.11.016_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109561","article-title":"Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: a study of 42 patients","volume":"150","author":"Caraballo","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.11.016_bib0051","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0052","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18544","article-title":"Comparative efficacy of neuromodulation therapies in Lennox-Gastaut syndrome: a systematic review and meta-analysis of vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation","author":"Samanta","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0053","article-title":"Successful treatment of pediatric patient with Dravet syndrome with cenobamate: case report","volume":"13","author":"Lobanov","year":"2025","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.seizure.2025.11.016_bib0054","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fphar.2020.01276","article-title":"Epilepsy-Related Voltage-Gated Sodium Channelopathies: a Review","volume":"11","author":"Menezes","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: a Placebo-Controlled Randomized Clinical Trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0056","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2025.11.016_bib0057","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pediatrneurol.2024.08.009","article-title":"Mammalian Target of Rapamycin Inhibitor Levels Decrease Under Cenobamate Treatment","volume":"161","author":"Becker","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0058","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/08830738211048326","article-title":"Focal Epilepsy in Children With Tuberous Sclerosis Complex: does Vigabatrin Control Focal Seizures?","volume":"37","author":"Lin","year":"2022","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0059","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.seizure.2025.07.018","article-title":"Severe epilepsy phenotypes in adults with succinic semialdehyde dehydrogenase deficiency: novel clinical and therapeutic insights from an Italian multicenter retrospective cohort study","volume":"131","author":"Canafoglia","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.11.016_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/19418744221147083","article-title":"Safe Use of Cenobamate in Super Refractory Status Epilepticus: a Case Series","volume":"13","author":"Carlson","year":"2023","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.seizure.2025.11.016_bib0061","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/epi.18115","article-title":"POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic-atonic seizures and ataxia","volume":"65","author":"Symonds","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0062","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/1871527321666220113110044","article-title":"Cenobamate: a Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy","volume":"22","author":"Barbieri","year":"2023","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.seizure.2025.11.016_bib0063","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/epi.17515","article-title":"A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam","volume":"64","author":"Elakkary","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.016_bib0064","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.3390\/jcm14176302","article-title":"Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: a Comprehensive Narrative Review","volume":"14","author":"Samanta","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.seizure.2025.11.016_bib0065","doi-asserted-by":"crossref","DOI":"10.1177\/08830738251357348","article-title":"Adverse Effects of Cenobamate in Pediatric Epilepsy: demographic Considerations","author":"Iwamoto","year":"2025","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2025.11.016_bib0066","series-title":"Neurology","first-page":"3535","article-title":"Effectiveness of Cenobamate in Pediatric Patients With Lennox-Gastaut Syndrome: a Retrospective Claims-based Analysis (P1-1.001)","author":"Keough","year":"2024"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125003188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125003188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:54:05Z","timestamp":1768348445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125003188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":66,"alternative-id":["S1059131125003188"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.11.016","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of cenobamate in developmental and epileptic encephalopathies: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}